Aktieanalys

Moberg Pharma Q2: In line with expectations – awaiting issue terms - Redeye

Redeye Publicerad: 03 Aug 2023 08:56

Redeye saw a report that was roughly in line with our expectations. The main events in the quarter have already been published where of course the EU recommendation is the primary with the delayed launch in a two-step model the second. The approval in Ireland is positive as it proves that the process is going forward and that more approvals will come in the coming quarters. This does not mean sales will commence in these countries but only in Scandinavia to start. The main topic we await is the subscription price in the upcoming share issue, due on 4 August at the latest. We will make minor adjustments to our estimates following the Q2 report.

Länk till analysen i sin helhet: https://www.redeye.se/research/927099/moberg-pharma-q2-in-line-with-expectations-awaiting-issue-terms?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!